Multiple Sclerosis Awareness Month: One man’s journey from diagnosis to advocacy
Multiple Sclerosis, also known as M.S. is a chronic autoimmune disease that affects the brain and spinal cord. While the way ...
NBC4 WCMH-TV53m
The Wellness Conversation: Exploring Multiple Sclerosis
Sponsor:  OhioHealth The latest episode of The Wellness Conversation – an OhioHealth Podcast, delves into the complexities of ...
‘Jacqueline du Pré: Genius and Tragedy’ Review: Bittersweet Strings on PBS
Yo-Yo Ma narrates a documentary about the remarkable cellist, whose life and career were cut short by multiple sclerosis.
Multiple Sclerosis News Today3h
Fatigue significantly contributes to impaired well-being in MS: Study
Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...
Multiple Sclerosis News Today7h
What I’ve learned from my aunt, who has secondary progressive MS
Chris Delemater says he's learned a lot from his aunt, Jenn Powell, who has MS, particularly about self-love and acceptance.
Medical Dialogues18h
Sanofi Tolebrutinib under USFDA priority review for multiple sclerosis
Tolebrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory ...
En Pareja on MSN9h
What is Multiple Sclerosis? The Condition Yolanda Andrade is Battling
After much speculation about her health, it has been revealed that Yolanda Andrade is dealing with multiple sclerosis. So, ...
Sanofi gets priority review for its multiple sclerosis treatment by FDA
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...
Applied Clinical Trials Online11h
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...
Sanofi: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to ...